Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial

The aim of this international phase II trial was to determine the efficacy and safety profile of weekly vinorelbine plus trastuzumab as first-line chemotherapy for women with HER 2-overexpressing metastatic breast cancer. Sixty-nine patients with tumours overexpressing HER 2 received vinorelbine: 30...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, A, Martin, M, Untch, M, Gil, M G, Guillem-Porta, V, Wojtukiewicz, M, Kellokumpu-Lehtinen, P, Sommer, H L, Georgoulias, V, Battelli, N, Pawlicki, M, Aubert, D, Bourlard, T, Gasmi, J, Villanova, G, Petruzelka, L
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360530/
https://www.ncbi.nlm.nih.gov/pubmed/16969343
http://dx.doi.org/10.1038/sj.bjc.6603351

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360530/
https://www.ncbi.nlm.nih.gov/pubmed/16969343
http://dx.doi.org/10.1038/sj.bjc.6603351

Ejemplares similares